Hemab Therapeutics Holdings Inc (COAG) Price Prediction & ForecastCOAGHemab Therapeutics Holdings Inc

Alphio's COAG stock price prediction model matches the current Hemab Therapeutics Holdings Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $35.53 (+0.54%). The 1-week path is $35.92 (+1.63%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Currently, Hemab Therapeutics Holdings, Inc. (COAG) is not a strong buy due to its recent performance and financial metrics. The stock closed at $30.07, down 4.90% over the last five days and 27.00% over the last 20 days. While the analyst consensus price target is $62.42, suggesting a potential upside of 105.68%, the company has reported significant net losses, with a net income of -24,150,000 USD in Q2 2026 and an EPS of -0.52. The RSI is at 42.221, indicating the stock is nearing oversold conditions, but the overall trend remains negative. Therefore, it may be prudent to hold rather than buy at this moment, as the stock may need time to stabilize and recover from its recent declines.

Hemab Therapeutics Holdings Inc (COAG) last closed at $35.34, gaining +3.42%. These facts feed the 1-day and 1-week COAG price prediction above.